A Phase 3 interventional study of CP-690,550 and CP-690,550 in Psoriasis, sponsored by Pfizer. Terminated at 323 sites in 36 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-26.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.
Among the 19 studies testing tofacitinib in Psoriasis, this one has the largest enrollment, is one of 3 that started in 2010, is one of 9 in phase 3, and was the 3rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Lahore General Hospital · Sites in Pakistan
Ages 18–70 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Pak Emirates Military Hospital
Ages 18–70
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,867 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 135 across the 19 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
57 studies in Psoriasis by Pfizer: none open now, none under way, none of them phase 3. Of 56 finished, 46 (82%) have results posted.
Among the 57 studies in Psoriasis by Pfizer, this one has the largest enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2010, is one of 10 in phase 3, and was the 29th registered.
Pfizer’s Psoriasis studies by the year they started, since 2002.
1 of the studies testing tofacitinib in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07581418Pak Emirates Military HospitalComparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing tofacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 57 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.
The study terminated on 08MAR2016 as it met its objectives of characterizing long term safety and tolerability. The study did not terminate due to safety concerns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study is anticipated to continue for up to at least 2 years post First Market Approval (FMA) in a global, major market. All subjects will receive 10 mg BID of CP-690,550 for first 3 months of trial. Study has the option for variable dosing with 5 mg or 10 mg BID after first 3-months of treatment based on PI discretion
Drug: CP-690,550
5 mg oral BID
10 mg oral BID
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 4 weeks after last dose (up to 67 months) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Number of Adverse Events (AEs) by Severity
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories: a) mild: AEs did not interfere with participant's usual function; b) moderate: AEs interfered to some extent with participant's usual function; c) severe: AEs interfered significantly with participant's usual function.
Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Number of Participants With Laboratory Abnormalities
Abnormality criteria: hematology (hemoglobin, hematocrit, red blood cell \<0.8\*lower limit of normal \[LLN\]; reticulocyte\<0.5\*LLN,\>1.5\*ULN; platelets\<0.5\*LLN,\>1.75\* upper limit of normal \[ULN\]; WBC\<0.6\*LLN, \>1.5\*ULN; lymphocytes, neutrophils, basophils, eosinophils, monocytes\<0.8\*LLN; \>1.2\*ULN; coagulation (prothrombin \[PT\], PT ratio\>1.1\*ULN) liver function (bilirubin\>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma GT\>0.3\*ULN, protein, albumin\<0.8\*LLN; \>1.2\*ULN, globulin\<0.5\*LLN; \>1.5\*ULN); renal function (blood urea nitrogen, creatinine\>1.3\*ULN); electrolytes(sodium\<0.95\* LLN; \>1.05\* ULN, potassium, chloride, calcium, bicarbonate\<0.9\*LLN; \>1.1\*ULN), chemistry (glucose\<0.6\*LLN; \>1.5\* ULN), urinalysis (pH \<4.5;\>8, glucose, ketones, protein, blood, urobilinogen, nitrite, bilirubin, leukocyte esterase\>=1; RBC, WBC\>=20); lipids (cholesterol \[C\], LDL-C \>1.3\*ULN, HDL-C\<0.8\*LLN, triglycerides\>1.3\* ULN), hormones(T4, T3, T4, TSH\<0.8\* LLN; \>1.2\* ULN).
Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Change From Baseline in Hemoglobin Level at Month 1
Time frame: Baseline, Month 1
Change From Baseline in Hemoglobin Level at Month 3
Time frame: Baseline, Month 3
Change From Baseline in Hemoglobin Level at Month 6
Time frame: Baseline, Month 6
Change From Baseline in Hemoglobin Level at Month 12
Time frame: Baseline, Month 12
Change From Baseline in Hemoglobin Level at Month 24
Time frame: Baseline, Month 24
Change From Baseline in Hemoglobin Level at Month 36
Time frame: Baseline, Month 36
Change From Baseline in Hemoglobin Level at Month 48
Time frame: Baseline, Month 48
Change From Baseline in Lymphocyte and Neutrophil Count at Month 1
Time frame: Baseline, Month 1
Change From Baseline in Lymphocyte and Neutrophil Count at Month 3
Time frame: Baseline, Month 3
Change From Baseline in Lymphocyte and Neutrophil Count at Month 6
Time frame: Baseline, Month 6
Change From Baseline in Lymphocyte and Neutrophil Count at Month 12
Time frame: Baseline, Month 12
Change From Baseline in Lymphocyte and Neutrophil Count at Month 24
Time frame: Baseline, Month 24
Change From Baseline in Lymphocyte and Neutrophil Count at Month 36
Time frame: Baseline, Month 36
Change From Baseline in Lymphocyte and Neutrophil Count at Month 48
Time frame: Baseline, Month 48
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 1
Time frame: Baseline, Month 1
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 3
Time frame: Baseline, Month 3
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 6
Time frame: Baseline, Month 6
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 12
Time frame: Baseline, Month 12
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 24
Time frame: Baseline, Month 24
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 36
Time frame: Baseline, Month 36
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 48
Time frame: Baseline, Month 48
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 1
Time frame: Baseline, Month 1
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 3
Time frame: Baseline, Month 3
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 6
Time frame: Baseline, Month 6
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 12
Time frame: Baseline, Month 12
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 24
Time frame: Baseline, Month 24
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 36
Time frame: Baseline, Month 36
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 48
Time frame: Baseline, Month 48
Number of Participants With Clinically Significant Change From Baseline in Physical Examination
Physical examinations included: general appearance; skin, head, eyes, ears, nose and throat; heart; lungs; abdomen; lower extremities (for the presence of peripheral edema) and lymph nodes. Clinical significance of change from baseline values in physical examination was based on investigator's discretion.
Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Number of Participants With Vital Sign Abnormalities
Criteria for abnormalities in vital signs included: Systolic blood pressure (SBP): less than (\<) 90 millimeter of mercury (mmHg) and maximum increase from baseline (IFB) of greater than or equal to (\>=) 30 mmHg; diastolic blood pressure (DBP): \<50 and greater than (\>) 120 mmHg and maximum IFB of \>=20 mmHg; heart rate: \<40 and \>120 beats per minute.
Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 1
Time frame: Baseline, Month 1
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 3
Time frame: Baseline, Month 3
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 6
Time frame: Baseline, Month 6
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 12
Time frame: Baseline, Month 12
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 24
Time frame: Baseline, Month 24
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 36
Time frame: Baseline, Month 36
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 48
Time frame: Baseline, Month 48
Change From Baseline in Heart Rate at Month 1
Time frame: Baseline, Month 1
Change From Baseline in Heart Rate at Month 3
Time frame: Baseline, Month 3
Change From Baseline in Heart Rate at Month 6
Time frame: Baseline, Month 6
Change From Baseline in Heart Rate at Month 12
Time frame: Baseline, Month 12
Change From Baseline in Heart Rate at Month 24
Time frame: Baseline, Month 24
Change From Baseline in Heart Rate at Month 36
Time frame: Baseline, Month 36
Change From Baseline in Heart Rate at Month 48
Time frame: Baseline, Month 48
Number of Participants With Electrocardiogram (ECG) Abnormalities
Criteria for ECG abnormality: PR interval \>=300 milliseconds (msec); QT interval \>=500 msec; QTcB (Bazett's Correction) and QTcF (Fridericia's Correction) 450 to \<480 msec, 480 to \<500 msec and \>=500 msec.
Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 6
Time frame: Baseline, Month 6
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 12
Time frame: Baseline, Month 12
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 24
Time frame: Baseline, Month 24
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 36
Time frame: Baseline, Month 36
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 48
Time frame: Baseline, Month 48
Number of Participants With Adjudicated Cardiovascular Events
Adjudicated cardiovascular events were assessed by adjudication committee as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; as applicable.
Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Number of Participants With Malignancy Events
Malignancy events included lymphoma, and demyelinating neurologic events. Biopsies collected for malignancy events were submitted to the central laboratory for pathologist over-read.
Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Percentage of Participants Achieving Physician Global Assessment (PGA) Response of 'Clear' or 'Almost Clear'
The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), induration (I), and scaling (S) across all psoriatic lesions in participants. The severity rating scores (Erythema: 0= no evidence of erythema to 4= dark, deep red; Induration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; Scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S = total) and the average (total/3) was taken. The total average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher score indicated more severity of psoriasis. Percentage of participants with response of 'clear' (score of '0') and 'almost clear' (score of '1') were reported.
Time frame: Month 1, 3, 6, 12, 24, 36, 48
Percentage of Participants Achieving Greater Than or Equal to (>=) 75 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=75 percent (%) reduction from baseline in PASI scores were reported.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Psoriasis Area and Severity Index (PASI) Scores
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores at Month 1, 3, 6, 12, 24, 36 and 48
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Psoriasis Area and Severity Index (PASI) Component Scores: Erythema
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Erythema was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Psoriasis Area and Severity Index (PASI) Component Scores: Induration
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Induration was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Psoriasis Area and Severity Index (PASI) Component Scores: Scaling
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Scaling was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Erythema at Month 1, 3, 6, 12, 24, 36 and 48
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Erythema was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Induration at Month 1, 3, 6, 12, 24, 36 and 48
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Induration was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Scaling at Month 1, 3, 6, 12, 24, 36 and 48
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Scaling was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=50% reduction from baseline in PASI scores were reported.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Percentage of Participants Achieving Greater Than or Equal to (>=) 90 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=90% reduction from baseline in PASI scores were reported.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Percentage of Participants Achieving Greater Than or Equal to (>=) 125 Percent Increase From Baseline in Psoriasis Area and Severity Index (PASI) Scores
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=125% increase from baseline in PASI scores were reported.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Itch Severity Item (ISI) Scores
ISI assessed severity of itching due to psoriasis. ISI was a single item, horizontal numeric rating scale. Participants were asked to rate their 'severity of itching' due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms '0=no itching' and '10=worst possible itching' at the ends. Higher scores indicated greater severity of itching.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Change From Baseline in Itch Severity Item (ISI) Scores at Month 1, 3, 6, 12, 24, 36 and 48
ISI assessed severity of itching due to psoriasis. ISI was a single item, horizontal numeric rating scale. Participants were asked to rate their 'severity of itching' due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms '0=no itching' and '10=worst possible itching' at the ends. Higher scores indicated greater severity of itching.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Dermatology Life Quality Index (DLQI) Scores
The DLQI was a validated, self-administered, 10-item quality-of-life questionnaire that consisted of 10 items that assessed the impact of skin disease on quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each question was scored on a scale of 0=not at all/not relevant to 3=very much. Response from all of the 10 questions were added to derive the DLQI total scores. Total DLQI scores ranges from 0=not at all to 30=very much, with higher scores indicating greater impairment in quality of life.
Time frame: Baseline, Month 1, 6, 12, 24, 36, 48
Change From Baseline in Dermatology Life Quality Index (DLQI) Scores at Month 1, 6, 12, 24, 36 and 48
The DLQI was a validated, self-administered, 10-item quality-of-life questionnaire that consisted of 10 items that assessed the impact of skin disease on quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each question was scored on a scale of 0=not at all/not relevant to 3=very much. Response from all of the 10 questions were added to derive the DLQI total scores. Total DLQI scores ranges from 0=not at all to 30=very much, with higher scores indicating greater impairment in quality of life.
Time frame: Baseline, Month 1, 6, 12, 24, 36, 48
36-Item Short-Form (SF-36) Health Survey Version 2, Acute: Physical Component Summary Scores
The SF-36 questionnaire, version 2, acute was a 36-item generic health status measure. SF-36 evaluated 8 health-related aspects of an individual: physical functioning, role-physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition. Two summary scale scores were computed from the 8 health aspect scores: physical component summary score and mental component summary score. Score range for both summary scales ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition.
Time frame: Baseline, Month 6, 12, 24, 36, 48
36-Item Short-Form (SF-36) Health Survey Version 2, Acute: Mental Component Summary Scores
The SF-36 questionnaire, version 2 was a 36-item generic health status measure. SF-36 evaluated 8 health-related aspects of an individual: physical functioning, role-physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition. Two summary scale scores were computed from the 8 health aspect scores: the Physical Component Summary and the Mental Component Summary. Score range for both summary scale ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition.
Time frame: Baseline, Month 6, 12, 24, 36, 48
Number of Participants With Patient Global Assessment (PtGA) Response of "Clear" or "Almost Clear"
The PtGA evaluated the overall skin disease of participants at that point in time on a single-item. Participants provided their response on a 5-point scale ranges from: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe. Higher score indicated greater severity of disease. Participants who provided their response as "clear (score of 0)" or "almost clear (score of 1)" in PtGA at each specified visit were reported in this outcome measure.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
Euro Quality of Life- 5-Dimensions (EQ-5D)-Utility Scores
EQ-5D: participant rated 5-dimension (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) questionnaire to assess health-related quality of life in terms of a single utility score. Each dimension was assessed on a 3-point scale (1=no problems, 2=some problems, 3=extreme problems, where higher scores=worse health condition). The responses from the 5 dimensions were used to calculate a single utility index value. Scoring formula developed by EuroQol Group assigned a utility value for each dimension in the profile. Score was transformed and results in a total score range -0.594 to 1.000; higher score indicated a better health state.
Time frame: Baseline, Month 6, 12, 24, 36, 48
Euro Quality of Life-5-Dimensions (EQ-5D)-Visual Analogue Scale Scores (VAS)
EQ-5D VAS was a participant rated questionnaire to assess health-related quality of life in terms of a single index value. It was a visual analogue scale that ranged from 0 (minimum) to 100 (maximum), with higher scores indicating a better health condition.
Time frame: Baseline, Month 6, 12, 24, 36, 48
Number of Participants Who Answered Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU)
Ps-HCRU was a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. In the first section, it assessed direct costs associated with healthcare resource use which included participant's interactions with healthcare providers such as general practitioners, dermatologists, cardiologists, gastroenterologists, psychiatrists, surgeons and nurses. When taking the evening dose of tofacitinib, participants were asked to answer the Ps-HCRU questionnaire only if they had an interaction with a healthcare provider or their work was impacted by psoriasis on that specified day. In this outcome measure, number of participants who answered Ps-HCRU at any specified visits were reported.
Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48
| Milestone | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Started | 2281 | 586 |
| Completed | 0 | 0 |
| Not completed | 2281 | 586 |
| Withdrew: Withdrawn due to pregnancy | 12 | 2 |
| Withdrew: Study terminated by sponsor | 978 | 349 |
| Withdrew: Protocol violation | 43 | 12 |
| Withdrew: Withdrawal by subject | 199 | 50 |
| Withdrew: Medication error | 1 | 0 |
| Withdrew: Lost to follow-up | 125 | 23 |
| Withdrew: Insufficient clinical response | 423 | 29 |
| Withdrew: Adverse event | 300 | 78 |
| Withdrew: Death | 17 | 5 |
| Withdrew: Ongoing | 13 | 4 |
| Withdrew: Other unspecified | 170 | 34 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 4 weeks after last dose (up to 67 months) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
| participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| AEs | 1876 | 490 |
| SAEs | 304 | 88 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories: a) mild: AEs did not interfere with participant's usual function; b) moderate: AEs interfered to some extent with participant's usual function; c) severe: AEs interfered significantly with participant's usual function.
| adverse events | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Mild | 5354 | 1749 |
| Moderate | 3268 | 766 |
| Severe | 410 | 136 |
Abnormality criteria: hematology (hemoglobin, hematocrit, red blood cell \<0.8\*lower limit of normal \[LLN\]; reticulocyte\<0.5\*LLN,\>1.5\*ULN; platelets\<0.5\*LLN,\>1.75\* upper limit of normal \[ULN\]; WBC\<0.6\*LLN, \>1.5\*ULN; lymphocytes, neutrophils, basophils, eosinophils, monocytes\<0.8\*LLN; \>1.2\*ULN; coagulation (prothrombin \[PT\], PT ratio\>1.1\*ULN) liver function (bilirubin\>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma GT\>0.3\*ULN, protein, albumin\<0.8\*LLN; \>1.2\*ULN, globulin\<0.5\*LLN; \>1.5\*ULN); renal function (blood urea nitrogen, creatinine\>1.3\*ULN); electrolytes(sodium\<0.95\* LLN; \>1.05\* ULN, potassium, chloride, calcium, bicarbonate\<0.9\*LLN; \>1.1\*ULN), chemistry (glucose\<0.6\*LLN; \>1.5\* ULN), urinalysis (pH \<4.5;\>8, glucose, ketones, protein, blood, urobilinogen, nitrite, bilirubin, leukocyte esterase\>=1; RBC, WBC\>=20); lipids (cholesterol \[C\], LDL-C \>1.3\*ULN, HDL-C\<0.8\*LLN, triglycerides\>1.3\* ULN), hormones(T4, T3, T4, TSH\<0.8\* LLN; \>1.2\* ULN).
| participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Number of Participants With Laboratory Abnormalities | 2203 | 565 |
| gram per deciliter (g/dL) | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline (n =2277, 586) | 14.64 ± 1.27 | 14.64 ± 1.24 |
| Change at Month 1 (n =2201, 563) | -0.24 ± 0.83 | -0.32 ± 0.86 |
| g/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Hemoglobin Level at Month 3 | -0.27 ± 0.85 | -0.39 ± 0.83 |
| g/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Hemoglobin Level at Month 6 | -0.27 ± 0.88 | -0.30 ± 0.87 |
| g/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Hemoglobin Level at Month 12 | -0.34 ± 0.93 | -0.30 ± 0.90 |
| g/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Hemoglobin Level at Month 24 | -0.30 ± 0.96 | -0.29 ± 0.89 |
| g/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Hemoglobin Level at Month 36 | -0.32 ± 0.93 | -0.37 ± 0.88 |
| g/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Hemoglobin Level at Month 48 | -0.35 ± 0.97 | -0.43 ± 0.94 |
| 1000 cells/mm^3 | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline: Lymphocyte Count (n =2275, 586) | 1.76 ± 0.57 | 1.80 ± 0.56 |
| Baseline: Neutrophil Count (n =2275, 586) | 4.74 ± 1.68 | 4.55 ± 1.70 |
| Change at Month 1: Lymphocyte Count (n =2182, 559) | 0.07 ± 0.52 | 0.11 ± 0.56 |
| Change at Month 1: Neutrophil Count (n =2182, 559) | -0.37 ± 1.65 | -0.48 ± 1.58 |
| 1000 cells/mm^3 | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Lymphocyte count | -0.00 ± 0.52 | 0.02 ± 0.52 |
| Neutrophil Count | -0.28 ± 1.63 | -0.28 ± 1.60 |
| 1000 cells/mm^3 | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Lymphocyte Count | -0.11 ± 0.51 | -0.05 ± 0.51 |
| Neutrophil Count | -0.25 ± 1.61 | -0.22 ± 1.64 |
| 1000 cells/mm^3 | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Lymphocyte Count | -0.21 ± 0.52 | -0.16 ± 0.48 |
| Neutrophil Count | -0.23 ± 1.61 | -0.18 ± 1.58 |
| 1000 cells/mm^3 | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Lymphocyte Count | -0.28 ± 0.52 | -0.18 ± 0.54 |
| Neutrophil Count | -0.19 ± 1.69 | -0.02 ± 1.59 |
| 1000 cells/mm^3 | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Lymphocyte Count | -0.35 ± 0.55 | -0.24 ± 0.51 |
| Neutrophil Count | -0.26 ± 1.61 | -0.11 ± 1.68 |
| 1000 cells/mm^3 | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Lymphocyte Count | -0.42 ± 0.52 | -0.27 ± 0.46 |
| Neutrophil Count | -0.28 ± 1.70 | -0.07 ± 1.49 |
| milligram per deciliter (mg/dL) | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline: Creatinine (n =2278, 586) | 0.90 ± 0.17 | 0.88 ± 0.16 |
| Baseline: LDL-C (n =2253, 585) | 114.14 ± 32.53 | 115.00 ± 35.03 |
| Baseline: HDL-C (n =2277, 586) | 49.05 ± 13.93 | 51.87 ± 17.33 |
| Baseline: TC (n =2277, 586) | 192.11 ± 38.10 | 194.96 ± 39.79 |
| Change at Month 1: Creatinine (n =2204, 563) | 0.03 ± 0.10 | 0.02 ± 0.10 |
| Change at Month 1: LDL-C (n =2125, 546) | 11.49 ± 28.77 | 11.55 ± 29.55 |
| Change at Month 1: HDL-C (n =2203, 562) | 8.19 ± 9.89 | 8.63 ± 10.50 |
| Change at Month 1: TC (n =2203, 562) | 21.12 ± 34.08 | 22.65 ± 34.36 |
| mg/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Creatinine (n =2211, 573) | 0.04 ± 0.21 | 0.03 ± 0.10 |
| LDL-C (n =2130, 559) | 11.97 ± 29.77 | 10.44 ± 32.72 |
| HDL-C (n =2204, 573) | 7.69 ± 10.23 | 7.96 ± 10.33 |
| TC (n =2203, 573) | 21.52 ± 35.63 | 21.06 ± 38.34 |
| mg/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Creatinine (n =2057, 564) | 0.03 ± 0.11 | 0.03 ± 0.10 |
| LDL-C (n =1983, 553) | 11.44 ± 30.10 | 8.74 ± 33.22 |
| HDL-C (n =2056, 564) | 7.68 ± 10.33 | 8.19 ± 11.60 |
| TC (n =2057, 564) | 20.91 ± 35.94 | 19.17 ± 39.06 |
| mg/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Creatinine (n =1777, 533) | 0.04 ± 0.12 | 0.04 ± 0.12 |
| LDL-C (n =1728, 521) | 11.31 ± 31.45 | 9.65 ± 32.87 |
| HDL-C (n =1776, 531) | 8.13 ± 10.48 | 6.88 ± 11.15 |
| TC (n =1776, 531) | 21.20 ± 39.15 | 16.97 ± 37.84 |
| mg/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Creatinine (n =1398, 450) | 0.05 ± 0.11 | 0.04 ± 0.11 |
| LDL-C (n =1353, 435) | 11.35 ± 35.33 | 10.13 ± 35.67 |
| HDL-C (n =1397, 450) | 9.02 ± 11.62 | 7.55 ± 11.94 |
| TC (n =1398, 450) | 21.74 ± 41.05 | 19.22 ± 39.69 |
| mg/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Creatinine (n =1122, 384) | 0.05 ± 0.12 | 0.04 ± 0.15 |
| LDL-C (n =1085, 375) | 10.11 ± 35.83 | 7.25 ± 37.41 |
| HDL-C (n =1119, 384) | 8.80 ± 11.59 | 6.39 ± 11.91 |
| TC (n =1119, 384) | 20.20 ± 41.28 | 15.55 ± 43.59 |
| mg/dL | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Creatinine (n =417, 127) | 0.04 ± 0.12 | 0.04 ± 0.11 |
| LDL-C (n =402, 123) | 12.98 ± 36.89 | 6.61 ± 34.66 |
| HDL-C (n =417, 127) | 8.62 ± 11.36 | 8.19 ± 12.72 |
| TC (n =417, 127) | 24.99 ± 43.35 | 16.36 ± 40.99 |
| international unit per liter (IU/L) | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline: AST (n =2278, 586) | 24.02 ± 12.22 | 24.66 ± 10.36 |
| Baseline: ALT (n =2278, 586) | 28.47 ± 17.29 | 28.17 ± 16.56 |
| Change at Month 1: AST (n =2198, 564) | 3.48 ± 15.39 | 4.07 ± 12.01 |
| Change at Month 1: ALT (n =2199, 564) | 4.07 ± 19.04 | 4.84 ± 17.50 |
| IU/L | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| AST (n =2200, 573) | 4.09 ± 17.75 | 5.65 ± 16.37 |
| ALT (n =2201, 573) | 4.86 ± 18.52 | 6.86 ± 20.80 |
| IU/L | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| AST (n =2052, 564) | 4.50 ± 15.60 | 5.07 ± 14.90 |
| ALT (n =2054, 564) | 5.98 ± 19.00 | 6.15 ± 18.40 |
| IU/L | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| AST (n =1772, 531) | 4.88 ± 16.63 | 7.29 ± 22.70 |
| ALT (n =1774, 532) | 6.68 ± 23.12 | 8.91 ± 25.21 |
| IU/L | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| AST (n =1397, 450) | 4.10 ± 14.64 | 6.77 ± 15.74 |
| ALT (n =1398, 450) | 5.31 ± 19.37 | 7.56 ± 18.93 |
| IU/L | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| AST | 5.38 ± 20.68 | 5.32 ± 15.65 |
| ALT | 5.46 ± 20.61 | 6.56 ± 22.43 |
| IU/L | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| AST (n =416, 127) | 4.49 ± 14.05 | 8.40 ± 26.41 |
| ALT (n =417, 127) | 4.92 ± 27.11 | 6.92 ± 20.98 |
Physical examinations included: general appearance; skin, head, eyes, ears, nose and throat; heart; lungs; abdomen; lower extremities (for the presence of peripheral edema) and lymph nodes. Clinical significance of change from baseline values in physical examination was based on investigator's discretion.
| participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Physical Examination | 683 | 191 |
Criteria for abnormalities in vital signs included: Systolic blood pressure (SBP): less than (\<) 90 millimeter of mercury (mmHg) and maximum increase from baseline (IFB) of greater than or equal to (\>=) 30 mmHg; diastolic blood pressure (DBP): \<50 and greater than (\>) 120 mmHg and maximum IFB of \>=20 mmHg; heart rate: \<40 and \>120 beats per minute.
| participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| SBP (n =2271, 577) | 12 | 6 |
| DBP (n =2271, 577) | 12 | 1 |
| Heart Rate (n =2271, 577) | 3 | 1 |
| Maximum IFB in SBP (n =2267, 577) | 187 | 65 |
| Maximum IFB in DBP (n =2267, 577) | 221 | 74 |
| millimeter of mercury (mmHg) | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline: Systolic BP (n =2277, 586) | 126.07 ± 14.03 | 126.24 ± 14.12 |
| Baseline: Diastolic BP (n =2277, 586) | 79.64 ± 9.42 | 78.88 ± 9.27 |
| Change at Month 1: Systolic BP (n =2210, 564) | -0.43 ± 11.83 | -1.31 ± 11.55 |
| Change at Month 1: Diastolic BP (n =2210, 564) | -0.03 ± 8.42 | 0.22 ± 8.45 |
| mmHg | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Systolic BP | -0.16 ± 11.97 | -0.95 ± 11.85 |
| Diastolic BP | -0.26 ± 8.56 | 0.05 ± 8.52 |
| mmHg | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Systolic BP | 0.22 ± 12.18 | -0.15 ± 12.48 |
| Diastolic BP | -0.05 ± 8.87 | 0.55 ± 8.74 |
| mmHg | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Systolic BP | 0.42 ± 11.97 | -0.20 ± 12.51 |
| Diastolic BP | 0.23 ± 8.89 | 0.10 ± 9.10 |
| mmHg | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Systolic BP | 0.84 ± 13.00 | -0.07 ± 13.02 |
| Diastolic BP | 0.36 ± 9.45 | 0.35 ± 8.85 |
| mmHg | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Systolic BP | 0.52 ± 13.15 | 0.10 ± 13.92 |
| Diastolic BP | 0.33 ± 9.33 | -0.06 ± 9.24 |
| mmHg | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Systolic BP | 2.35 ± 13.45 | 1.13 ± 15.18 |
| Diastolic BP | 0.97 ± 9.52 | 0.87 ± 9.80 |
| beats per minute | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline (n =2277, 586) | 71.81 ± 9.67 | 71.46 ± 9.93 |
| Change at Month 1 (n =2210, 563) | -0.82 ± 9.16 | -1.23 ± 9.03 |
| beats per minute | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Heart Rate at Month 3 | -0.57 ± 9.35 | -0.32 ± 9.19 |
| beats per minute | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Heart Rate at Month 6 | -0.73 ± 9.65 | -1.05 ± 9.18 |
| beats per minute | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Heart Rate at Month 12 | -1.13 ± 9.66 | -1.14 ± 9.07 |
| beats per minute | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Heart Rate at Month 24 | -1.07 ± 9.91 | -0.94 ± 8.89 |
| beats per minute | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Heart Rate at Month 36 | -1.38 ± 9.81 | -1.00 ± 9.26 |
| beats per minute | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Change From Baseline in Heart Rate at Month 48 | -0.91 ± 10.64 | -0.64 ± 10.64 |
Criteria for ECG abnormality: PR interval \>=300 milliseconds (msec); QT interval \>=500 msec; QTcB (Bazett's Correction) and QTcF (Fridericia's Correction) 450 to \<480 msec, 480 to \<500 msec and \>=500 msec.
| participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Number of Participants With Electrocardiogram (ECG) Abnormalities | 7 | 2 |
| milliseconds (msec) | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline: QRS Complex (n =2264, 583) | 92.88 ± 9.12 | 92.31 ± 9.75 |
| Baseline: PR Interval (n =2258, 583) | 162.32 ± 21.32 | 158.91 ± 20.62 |
| Baseline: QT Interval (n =2264, 583) | 392.39 ± 29.12 | 395.75 ± 29.70 |
| Baseline: QTcB Interval (n =2264, 583) | 415.70 ± 23.83 | 416.91 ± 23.04 |
| Baseline: QTcF Interval (n =2264, 583) | 407.48 ± 20.74 | 409.42 ± 20.11 |
| Baseline: RR Interval (n =2264, 583) | 901.27 ± 145.58 | 911.59 ± 150.35 |
| Change at Month 6: QRS Complex (n =1995, 550) | 1.51 ± 8.28 | 2.01 ± 7.50 |
| Change at Month 6: PR Interval (n =1986, 549) | 2.46 ± 13.79 | 2.76 ± 14.81 |
| Change at Month 6: QT Interval (n =1995, 550) | 2.25 ± 24.49 | 2.52 ± 24.39 |
| Change at Month 6: QTcB Interval (n =1995, 550) | -0.84 ± 20.49 | -1.38 ± 20.31 |
| Change at Month 6: QTcF Interval (n =1995, 550) | 0.23 ± 17.14 | -0.03 ± 17.68 |
| Change at Month 6: RR Interval (n =1995, 550) | 14.35 ± 130.91 | 18.77 ± 123.49 |
| msec | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| QRS Complex (n =1726, 516) | 1.89 ± 7.93 | 2.11 ± 7.53 |
| PR Interval (n =1717, 515) | 2.80 ± 14.32 | 3.21 ± 14.31 |
| QT Interval (n =1726, 516) | 2.49 ± 23.26 | 2.69 ± 23.00 |
| QTcB Interval (n =1726, 516) | -1.04 ± 20.63 | -1.09 ± 20.83 |
| QTcF Interval (n =1726, 516) | 0.16 ± 16.71 | 0.23 ± 17.20 |
| RR Interval (n =1727, 516) | 15.94 ± 130.60 | 17.55 ± 128.16 |
| msec | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| QRS Complex (n =1352, 432) | 2.00 ± 8.55 | 2.42 ± 9.13 |
| PR Interval (n =1346, 432) | 3.49 ± 14.55 | 3.81 ± 14.67 |
| QT Interval (n =1352, 432) | 3.93 ± 24.93 | 2.28 ± 24.80 |
| QTcB Interval (n =1352, 431) | 0.15 ± 20.77 | 0.78 ± 21.06 |
| QTcF Interval (n =1352, 431) | 1.47 ± 16.86 | 1.25 ± 17.72 |
| RR Interval (n =1352, 432) | 17.70 ± 139.47 | 8.66 ± 135.06 |
| msec | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| QRS Complex (n =845, 283) | 1.75 ± 8.47 | 1.85 ± 10.37 |
| PR Interval (n =840, 282) | 4.18 ± 14.50 | 3.25 ± 15.50 |
| QT Interval (n =844, 283) | 4.31 ± 24.93 | 2.52 ± 22.63 |
| QTcB Interval (n =844, 283) | 0.44 ± 21.29 | -0.01 ± 22.21 |
| QTcF Interval (n =844, 283) | 1.79 ± 17.57 | 0.84 ± 17.63 |
| RR Interval (n =845, 283) | 18.24 ± 136.44 | 15.14 ± 131.42 |
| msec | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| QRS Complex (n =126, 55) | 2.37 ± 10.17 | 1.31 ± 5.37 |
| PR Interval (n =126, 55) | 6.26 ± 12.58 | 1.98 ± 13.20 |
| QT Interval (n =126, 55) | 6.43 ± 24.05 | 1.69 ± 23.43 |
| QTcB Interval (n =125, 55) | 3.42 ± 20.11 | -2.00 ± 22.64 |
| QTcF Interval (n =125, 55) | 4.55 ± 15.84 | -0.87 ± 19.38 |
| RR Interval (n =126, 55) | 15.69 ± 143.06 | 20.78 ± 119.61 |
Adjudicated cardiovascular events were assessed by adjudication committee as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; as applicable.
| participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Number of Participants With Adjudicated Cardiovascular Events | 32 | 13 |
Malignancy events included lymphoma, and demyelinating neurologic events. Biopsies collected for malignancy events were submitted to the central laboratory for pathologist over-read.
| participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Number of Participants With Malignancy Events | 87 | 26 |
The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), induration (I), and scaling (S) across all psoriatic lesions in participants. The severity rating scores (Erythema: 0= no evidence of erythema to 4= dark, deep red; Induration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; Scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S = total) and the average (total/3) was taken. The total average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher score indicated more severity of psoriasis. Percentage of participants with response of 'clear' (score of '0') and 'almost clear' (score of '1') were reported.
| percentage of participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1 (n =2196, 563) | 50.36 (48.27 to 52.46) | 77.80 (74.36 to 81.23) |
| Month 3 (n =2200, 571) | 54.86 (52.78 to 56.94) | 85.29 (82.38 to 88.19) |
| Month 6 (n =2052, 564) | 54.97 (52.82 to 57.12) | 82.09 (78.93 to 85.26) |
| Month 12 (n =1776, 532) | 54.79 (52.47 to 57.10) | 75.19 (71.52 to 78.86) |
| Month 24 (n =1397, 448) | 54.62 (52.01 to 57.23) | 79.46 (75.72 to 83.20) |
| Month 36 (n =1123, 385) | 57.35 (54.45 to 60.24) | 76.36 (72.12 to 80.61) |
| Month 48 (n =422, 126) | 48.58 (43.81 to 53.35) | 77.78 (70.52 to 85.04) |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=75 percent (%) reduction from baseline in PASI scores were reported.
| percentage of participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1 (n =2194, 555) | 51.96 (49.87 to 54.05) | 71.89 (68.15 to 75.63) |
| Month 3 (n =2200, 566) | 58.45 (56.40 to 60.51) | 84.45 (81.47 to 87.44) |
| Month 6 (n =2048, 557) | 61.67 (59.56 to 63.78) | 86.00 (83.11 to 88.88) |
| Month 12 (n =1775, 525) | 65.24 (63.02 to 67.45) | 80.76 (77.39 to 84.13) |
| Month 24 (n =1393, 445) | 67.26 (64.80 to 69.73) | 84.94 (81.62 to 88.27) |
| Month 36 (n =1118, 380) | 70.75 (68.08 to 73.42) | 83.95 (80.26 to 87.64) |
| Month 48 (n =422, 124) | 64.93 (60.38 to 69.48) | 83.06 (76.46 to 89.67) |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline (n =2266, 585) | 21.85 ± 9.48 | 19.05 ± 8.89 |
| Month 1 (n =2198, 561) | 6.60 ± 7.14 | 3.09 ± 4.81 |
| Month 3 (n =2205, 572) | 5.64 ± 6.33 | 1.95 ± 3.25 |
| Month 6 (n =2051, 563) | 5.31 ± 6.31 | 1.90 ± 3.25 |
| Month 12 (n =1779, 531) | 4.72 ± 5.29 | 2.38 ± 3.57 |
| Month 24 (n =1397, 449) | 4.41 ± 5.08 | 1.90 ± 2.65 |
| Month 36 (n =1121, 384) | 3.91 ± 4.66 | 2.19 ± 3.23 |
| Month 48 (n =422, 126) | 4.75 ± 5.37 | 1.85 ± 2.31 |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1 (n =2195, 561) | -15.26 ± 9.96 | -16.00 ± 9.57 |
| Month 3 (n =2201, 572) | -16.18 ± 9.73 | -16.99 ± 9.27 |
| Month 6 (n =2049, 563) | -16.56 ± 9.54 | -17.03 ± 9.16 |
| Month 12 (n =1776, 531) | -17.01 ± 9.33 | -16.45 ± 9.04 |
| Month 24 (n =1394, 449) | -17.25 ± 9.35 | -16.67 ± 8.70 |
| Month 36 (n =1119, 384) | -17.44 ± 9.23 | -16.49 ± 8.81 |
| Month 48 (n =422, 126) | -16.16 ± 8.61 | -15.47 ± 9.04 |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Erythema was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline: Head/Neck (n =2266, 585) | 2.26 ± 0.99 | 2.13 ± 1.08 |
| Month 1: Head/Neck (n =2198, 561) | 0.82 ± 0.96 | 0.47 ± 0.81 |
| Month 3: Head/Neck (n =2205, 572) | 0.76 ± 0.95 | 0.34 ± 0.65 |
| Month 6: Head/Neck (n =2051, 563) | 0.75 ± 0.95 | 0.42 ± 0.75 |
| Month 12: Head/Neck (n =1779, 531) | 0.70 ± 0.92 | 0.49 ± 0.82 |
| Month 24: Head/Neck (n =1397, 449) | 0.66 ± 0.93 | 0.47 ± 0.75 |
| Month 36: Head/Neck (n =1121, 384) | 0.57 ± 0.88 | 0.48 ± 0.79 |
| Month 48: Head/Neck (n =422, 126) | 0.70 ± 0.93 | 0.34 ± 0.69 |
| Baseline: Upper Limbs (n =2266, 585) | 2.82 ± 0.74 | 2.68 ± 0.86 |
| Month 1: Upper Limbs (n =2198, 561) | 1.29 ± 0.98 | 0.71 ± 0.86 |
| Month 3: Upper Limbs (n =2205, 572) | 1.23 ± 1.00 | 0.57 ± 0.79 |
| Month 6: Upper Limbs (n =2051, 563) | 1.20 ± 1.01 | 0.58 ± 0.83 |
| Month 12: Upper Limbs (n =1779, 531) | 1.16 ± 1.01 | 0.74 ± 0.95 |
| Month 24: Upper Limbs (n =1397, 449) | 1.13 ± 1.03 | 0.61 ± 0.85 |
| Month 36: Upper Limbs (n =1121, 384) | 1.06 ± 1.01 | 0.68 ± 0.86 |
| Month 48: Upper Limbs (n =422, 126) | 1.18 ± 1.03 | 0.58 ± 0.84 |
| Baseline: Trunk (n =2266, 585) | 2.83 ± 0.83 | 2.73 ± 0.94 |
| Month 1: Trunk (n =2198, 561) | 1.18 ± 1.11 | 0.62 ± 0.92 |
| Month 3: Trunk (n =2205, 572) | 1.06 ± 1.09 | 0.41 ± 0.73 |
| Month 6: Trunk (n =2051, 563) | 1.03 ± 1.09 | 0.41 ± 0.79 |
| Month 12: Trunk (n =1779, 531) | 0.99 ± 1.08 | 0.51 ± 0.89 |
| Month 24: Trunk (n =1397, 449) | 0.96 ± 1.08 | 0.49 ± 0.84 |
| Month 36: Trunk (n =1121, 384) | 0.86 ± 1.06 | 0.53 ± 0.90 |
| Month 48: Trunk (n =422, 126) | 1.00 ± 1.10 | 0.50 ± 0.86 |
| Baseline: Lower Limbs (n =2266, 585) | 3.10 ± 0.70 | 2.94 ± 0.89 |
| Month 1: Lower Limbs (n =2198, 561) | 1.37 ± 1.09 | 0.79 ± 0.95 |
| Month 3: Lower Limbs (n =2205, 572) | 1.24 ± 1.08 | 0.58 ± 0.84 |
| Month 6: Lower Limbs (n =2051, 563) | 1.20 ± 1.11 | 0.52 ± 0.81 |
| Month 12: Lower Limbs (n =1779, 531) | 1.17 ± 1.10 | 0.69 ± 0.98 |
| Month 24: Lower Limbs (n =1397, 449) | 1.15 ± 1.11 | 0.59 ± 0.90 |
| Month 36: Lower Limbs (n =1121, 384) | 1.07 ± 1.11 | 0.67 ± 0.96 |
| Month 48: Lower Limbs (n =422, 126) | 1.20 ± 1.11 | 0.61 ± 0.91 |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Induration was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline: Head/Neck (n =2266, 585) | 1.97 ± 1.01 | 1.88 ± 1.10 |
| Month 1: Head/Neck (n =2198, 561) | 0.65 ± 0.85 | 0.35 ± 0.73 |
| Month 3: Head/Neck (n =2205, 572) | 0.60 ± 0.84 | 0.26 ± 0.56 |
| Month 6: Head/Neck (n =2051, 563) | 0.59 ± 0.86 | 0.31 ± 0.67 |
| Month 12: Head/Neck (n =1779, 531) | 0.55 ± 0.81 | 0.38 ± 0.71 |
| Month 24: Head/Neck (n =1397, 449) | 0.53 ± 0.82 | 0.37 ± 0.68 |
| Month 36: Head/Neck (n =1121, 384) | 0.46 ± 0.77 | 0.37 ± 0.68 |
| Month 48: Head/Neck (n =422, 126) | 0.60 ± 0.85 | 0.26 ± 0.60 |
| Baseline: Upper Limbs (n =2266, 585) | 2.64 ± 0.77 | 2.50 ± 0.93 |
| Month 1: Upper Limbs (n =2198, 561) | 1.21 ± 0.99 | 0.66 ± 0.88 |
| Month 3: Upper Limbs (n =2205, 572) | 1.17 ± 1.01 | 0.53 ± 0.81 |
| Month 6: Upper Limbs (n =2051, 563) | 1.15 ± 1.02 | 0.55 ± 0.85 |
| Month 12: Upper Limbs (n =1779, 531) | 1.11 ± 1.01 | 0.69 ± 0.95 |
| Month 24: Upper Limbs (n =1397, 449) | 1.08 ± 1.02 | 0.53 ± 0.84 |
| Month 36: Upper Limbs (n =1121, 384) | 1.00 ± 1.01 | 0.60 ± 0.82 |
| Month 48: Upper Limbs (n =422, 126) | 1.09 ± 1.00 | 0.50 ± 0.75 |
| Baseline: Trunk (n =2266, 585) | 2.57 ± 0.86 | 2.51 ± 1.01 |
| Month 1: Trunk (n =2198, 561) | 1.02 ± 1.04 | 0.52 ± 0.86 |
| Month 3: Trunk (n =2205, 572) | 0.91 ± 1.02 | 0.34 ± 0.68 |
| Month 6: Trunk (n =2051, 563) | 0.88 ± 1.00 | 0.34 ± 0.71 |
| Month 12: Trunk (n =1779, 531) | 0.87 ± 1.00 | 0.42 ± 0.77 |
| Month 24: Trunk (n =1397, 449) | 0.82 ± 0.98 | 0.39 ± 0.73 |
| Month 36: Trunk (n =1121, 384) | 0.75 ± 0.97 | 0.43 ± 0.79 |
| Month 48: Trunk (n =422, 126) | 0.91 ± 1.05 | 0.44 ± 0.80 |
| Baseline: Lower Limbs (n =2266, 585) | 2.85 ± 0.76 | 2.77 ± 0.96 |
| Month 1: Lower Limbs (n =2198, 561) | 1.22 ± 1.04 | 0.68 ± 0.95 |
| Month 3: Lower Limbs (n =2205, 572) | 1.10 ± 1.04 | 0.51 ± 0.84 |
| Month 6: Lower Limbs (n =2051, 563) | 1.08 ± 1.06 | 0.47 ± 0.82 |
| Month 12: Lower Limbs (n =1779, 531) | 1.05 ± 1.03 | 0.61 ± 0.94 |
| Month 24: Lower Limbs (n =1397, 449) | 1.02 ± 1.03 | 0.49 ± 0.83 |
| Month 36: Lower Limbs (n =1121, 384) | 0.95 ± 1.03 | 0.57 ± 0.87 |
| Month 48: Lower Limbs (n =422, 126) | 1.07 ± 1.04 | 0.48 ± 0.79 |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Scaling was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline: Head/Neck (n =2266, 585) | 2.22 ± 1.08 | 2.10 ± 1.11 |
| Month 1: Head/Neck (n =2198, 561) | 0.75 ± 0.95 | 0.42 ± 0.79 |
| Month 3: Head/Neck (n =2205, 572) | 0.71 ± 0.95 | 0.32 ± 0.66 |
| Month 6: Head/Neck (n =2051, 563) | 0.71 ± 0.97 | 0.40 ± 0.77 |
| Month 12: Head/Neck (n =1779, 531) | 0.67 ± 0.92 | 0.48 ± 0.84 |
| Month 24: Head/Neck (n =1397, 449) | 0.60 ± 0.88 | 0.45 ± 0.77 |
| Month 36: Head/Neck (n =1121, 384) | 0.55 ± 0.88 | 0.47 ± 0.79 |
| Month 48: Head/Neck (n =422, 126) | 0.65 ± 0.93 | 0.34 ± 0.72 |
| Baseline: Upper Limbs (n =2266, 585) | 2.65 ± 0.82 | 2.52 ± 0.96 |
| Month 1: Upper Limbs (n =2198, 561) | 1.22 ± 1.01 | 0.69 ± 0.89 |
| Month 3: Upper Limbs (n =2205, 572) | 1.18 ± 1.04 | 0.55 ± 0.80 |
| Month 6: Upper Limbs (n =2051, 563) | 1.16 ± 1.05 | 0.58 ± 0.87 |
| Month 12: Upper Limbs (n =1779, 531) | 1.12 ± 1.03 | 0.72 ± 0.97 |
| Month 24: Upper Limbs (n =1397, 449) | 1.08 ± 1.03 | 0.58 ± 0.84 |
| Month 36: Upper Limbs (n =1121, 384) | 1.01 ± 1.02 | 0.62 ± 0.83 |
| Month 48: Upper Limbs (n =422, 126) | 1.13 ± 1.09 | 0.53 ± 0.79 |
| Baseline: Trunk (n =2266, 585) | 2.55 ± 0.89 | 2.47 ± 1.00 |
| Month 1: Trunk (n =2198, 561) | 0.97 ± 1.02 | 0.50 ± 0.83 |
| Month 3: Trunk (n =2205, 572) | 0.87 ± 1.00 | 0.33 ± 0.64 |
| Month 6: Trunk (n =2051, 563) | 0.85 ± 0.99 | 0.33 ± 0.70 |
| Month 12: Trunk (n =1779, 531) | 0.83 ± 0.97 | 0.40 ± 0.76 |
| Month 24: Trunk (n =1397, 449) | 0.78 ± 0.95 | 0.39 ± 0.72 |
| Month 36: Trunk (n =1121, 384) | 0.71 ± 0.93 | 0.42 ± 0.77 |
| Month 48: Trunk (n =422, 126) | 0.86 ± 0.99 | 0.40 ± 0.78 |
| Baseline: Lower Limbs (n =2266, 585) | 2.89 ± 0.81 | 2.79 ± 1.00 |
| Month 1: Lower Limbs (n =2198, 561) | 1.23 ± 1.08 | 0.70 ± 0.93 |
| Month 3: Lower Limbs (n =2205, 572) | 1.12 ± 1.08 | 0.48 ± 0.78 |
| Month 6: Lower Limbs (n =2051, 563) | 1.11 ± 1.10 | 0.48 ± 0.83 |
| Month 12: Lower Limbs (n =1779, 531) | 1.07 ± 1.07 | 0.64 ± 0.98 |
| Month 24: Lower Limbs (n =1397, 449) | 1.04 ± 1.06 | 0.53 ± 0.84 |
| Month 36: Lower Limbs (n =1121, 384) | 0.94 ± 1.03 | 0.60 ± 0.90 |
| Month 48: Lower Limbs (n =422, 126) | 1.09 ± 1.09 | 0.48 ± 0.76 |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Erythema was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1: Head/Neck (n =2195, 561) | -1.43 ± 1.15 | -1.66 ± 1.20 |
| Month 3: Head/Neck (n =2201, 572) | -1.50 ± 1.18 | -1.80 ± 1.18 |
| Month 6: Head/Neck (n =2049, 563) | -1.52 ± 1.20 | -1.72 ± 1.21 |
| Month 12: Head/Neck (n =1776, 531) | -1.56 ± 1.19 | -1.64 ± 1.22 |
| Month 24: Head/Neck (n =1394, 449) | -1.62 ± 1.19 | -1.67 ± 1.23 |
| Month 36: Head/Neck (n =1119, 384) | -1.72 ± 1.18 | -1.67 ± 1.20 |
| Month 48: Head/Neck (n =422, 126) | -1.55 ± 1.19 | -1.70 ± 1.13 |
| Month 1: Upper Limbs (n =2195, 561) | -1.53 ± 1.12 | -1.98 ± 1.18 |
| Month 3: Upper Limbs (n =2201, 572) | -1.59 ± 1.15 | -2.12 ± 1.14 |
| Month 6: Upper Limbs (n =2049, 563) | -1.62 ± 1.15 | -2.09 ± 1.13 |
| Month 12: Upper Limbs (n =1776, 531) | -1.67 ± 1.15 | -1.94 ± 1.21 |
| Month 24: Upper Limbs (n =1394, 449) | -1.70 ± 1.18 | -2.05 ± 1.19 |
| Month 36: Upper Limbs (n =1119, 384) | -1.78 ± 1.17 | -2.00 ± 1.18 |
| Month 48: Upper Limbs (n =422, 126) | -1.62 ± 1.16 | -1.90 ± 1.22 |
| Month 1: Trunk (n =2195, 561) | -1.65 ± 1.22 | -2.12 ± 1.26 |
| Month 3: Trunk (n =2201, 572) | -1.77 ± 1.24 | -2.33 ± 1.17 |
| Month 6: Trunk (n =2049, 563) | -1.81 ± 1.24 | -2.32 ± 1.19 |
| Month 12: Trunk (n =1776, 531) | -1.86 ± 1.24 | -2.21 ± 1.25 |
| Month 24: Trunk (n =1394, 449) | -1.88 ± 1.25 | -2.22 ± 1.26 |
| Month 36: Trunk (n =1119, 384) | -1.99 ± 1.26 | -2.18 ± 1.30 |
| Month 48: Trunk (n =422, 126) | -1.82 ± 1.22 | -2.08 ± 1.17 |
| Month 1: Lower Limbs (n =2195, 561) | -1.72 ± 1.19 | -2.16 ± 1.26 |
| Month 3: Lower Limbs (n =2201, 572) | -1.87 ± 1.21 | -2.36 ± 1.21 |
| Month 6: Lower Limbs (n =2049, 563) | -1.90 ± 1.22 | -2.42 ± 1.18 |
| Month 12: Lower Limbs (n =1776, 531) | -1.94 ± 1.23 | -2.24 ± 1.33 |
| Month 24: Lower Limbs (n =1394, 449) | -1.95 ± 1.25 | -2.32 ± 1.24 |
| Month 36: Lower Limbs (n =1119, 384) | -2.04 ± 1.23 | -2.28 ± 1.30 |
| Month 48: Lower Limbs (n =422, 126) | -1.87 ± 1.20 | -2.17 ± 1.21 |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Induration was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1: Head/Neck (n =2195, 561) | -1.32 ± 1.13 | -1.53 ± 1.15 |
| Month 3: Head/Neck (n =2201, 572) | -1.37 ± 1.17 | -1.63 ± 1.14 |
| Month 6: Head/Neck (n =2049, 563) | -1.40 ± 1.16 | -1.57 ± 1.18 |
| Month 12: Head/Neck (n =1776, 531) | -1.44 ± 1.18 | -1.49 ± 1.18 |
| Month 24: Head/Neck (n =1394, 449) | -1.48 ± 1.17 | -1.51 ± 1.21 |
| Month 36: Head/Neck (n =1119, 384) | -1.55 ± 1.17 | -1.51 ± 1.15 |
| Month 48: Head/Neck (n =422, 126) | -1.35 ± 1.17 | -1.41 ± 1.10 |
| Month 1: Upper Limbs (n =2195, 561) | -1.43 ± 1.14 | -1.85 ± 1.22 |
| Month 3: Upper Limbs (n =2201, 572) | -1.47 ± 1.17 | -1.97 ± 1.16 |
| Month 6: Upper Limbs (n =2049, 563) | -1.49 ± 1.15 | -1.94 ± 1.19 |
| Month 12: Upper Limbs (n =1776, 531) | -1.54 ± 1.14 | -1.82 ± 1.27 |
| Month 24: Upper Limbs (n =1394, 449) | -1.57 ± 1.18 | -1.97 ± 1.19 |
| Month 36: Upper Limbs (n =1119, 384) | -1.65 ± 1.17 | -1.92 ± 1.18 |
| Month 48: Upper Limbs (n =422, 126) | -1.53 ± 1.14 | -1.83 ± 1.14 |
| Month 1: Trunk (n =2195, 561) | -1.55 ± 1.19 | -2.01 ± 1.26 |
| Month 3: Trunk (n =2201, 572) | -1.65 ± 1.22 | -2.17 ± 1.18 |
| Month 6: Trunk (n =2049, 563) | -1.70 ± 1.19 | -2.18 ± 1.20 |
| Month 12: Trunk (n =1776, 531) | -1.71 ± 1.20 | -2.10 ± 1.24 |
| Month 24: Trunk (n =1394, 449) | -1.76 ± 1.19 | -2.13 ± 1.20 |
| Month 36: Trunk (n =1119, 384) | -1.85 ± 1.20 | -2.09 ± 1.23 |
| Month 48: Trunk (n =422, 126) | -1.68 ± 1.17 | -1.87 ± 1.20 |
| Month 1: Lower Limbs (n =2195, 561) | -1.63 ± 1.22 | -2.09 ± 1.31 |
| Month 3: Lower Limbs (n =2201, 572) | -1.75 ± 1.22 | -2.26 ± 1.24 |
| Month 6: Lower Limbs (n =2049, 563) | -1.78 ± 1.23 | -2.30 ± 1.23 |
| Month 12: Lower Limbs (n =1776, 531) | -1.82 ± 1.20 | -2.17 ± 1.33 |
| Month 24: Lower Limbs (n =1394, 449) | -1.85 ± 1.22 | -2.28 ± 1.24 |
| Month 36: Lower Limbs (n =1119, 384) | -1.93 ± 1.21 | -2.22 ± 1.29 |
| Month 48: Lower Limbs (n =422, 126) | -1.77 ± 1.18 | -2.07 ± 1.24 |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Scaling was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1: Head/Neck (n =2195, 561) | -1.46 ± 1.19 | -1.69 ± 1.20 |
| Month 3: Head/Neck (n =2201, 572) | -1.51 ± 1.24 | -1.78 ± 1.19 |
| Month 6: Head/Neck (n =2049, 563) | -1.52 ± 1.24 | -1.70 ± 1.22 |
| Month 12: Head/Neck (n =1776, 531) | -1.56 ± 1.25 | -1.61 ± 1.24 |
| Month 24: Head/Neck (n =1394, 449) | -1.63 ± 1.24 | -1.63 ± 1.27 |
| Month 36: Head/Neck (n =1119, 384) | -1.68 ± 1.22 | -1.64 ± 1.22 |
| Month 48: Head/Neck (n =422, 126) | -1.53 ± 1.24 | -1.58 ± 1.17 |
| Month 1: Upper Limbs (n =2195, 561) | -1.44 ± 1.18 | -1.84 ± 1.24 |
| Month 3: Upper Limbs (n =2201, 572) | -1.47 ± 1.20 | -1.97 ± 1.18 |
| Month 6: Upper Limbs (n =2049, 563) | -1.49 ± 1.21 | -1.94 ± 1.26 |
| Month 12: Upper Limbs (n =1776, 531) | -1.52 ± 1.21 | -1.82 ± 1.30 |
| Month 24: Upper Limbs (n =1394, 449) | -1.56 ± 1.22 | -1.96 ± 1.22 |
| Month 36: Upper Limbs (n =1119, 384) | -1.65 ± 1.19 | -1.93 ± 1.15 |
| Month 48: Upper Limbs (n =422, 126) | -1.45 ± 1.19 | -1.78 ± 1.22 |
| Month 1: Trunk (n =2195, 561) | -1.58 ± 1.20 | -1.98 ± 1.24 |
| Month 3: Trunk (n =2201, 572) | -1.67 ± 1.22 | -2.14 ± 1.14 |
| Month 6: Trunk (n =2049, 563) | -1.70 ± 1.19 | -2.14 ± 1.22 |
| Month 12: Trunk (n =1776, 531) | -1.72 ± 1.21 | -2.08 ± 1.23 |
| Month 24: Trunk (n =1394, 449) | -1.77 ± 1.20 | -2.11 ± 1.19 |
| Month 36: Trunk (n =1119, 384) | -1.84 ± 1.20 | -2.06 ± 1.23 |
| Month 48: Trunk (n =422, 126) | -1.62 ± 1.19 | -1.80 ± 1.18 |
| Month 1: Lower Limbs (n =2195, 561) | -1.67 ± 1.24 | -2.09 ± 1.30 |
| Month 3: Lower Limbs (n =2201, 572) | -1.77 ± 1.26 | -2.30 ± 1.23 |
| Month 6: Lower Limbs (n =2049, 563) | -1.79 ± 1.27 | -2.30 ± 1.25 |
| Month 12: Lower Limbs (n =1776, 531) | -1.83 ± 1.26 | -2.15 ± 1.36 |
| Month 24: Lower Limbs (n =1394, 449) | -1.86 ± 1.27 | -2.25 ± 1.24 |
| Month 36: Lower Limbs (n =1119, 384) | -1.97 ± 1.23 | -2.21 ± 1.26 |
| Month 48: Lower Limbs (n =422, 126) | -1.77 ± 1.29 | -2.11 ± 1.23 |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=50% reduction from baseline in PASI scores were reported.
| percentage of participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1 (n =2194, 555) | 76.53 (74.75 to 78.30) | 86.67 (83.84 to 89.49) |
| Month 3 (n =2200, 566) | 81.59 (79.97 to 83.21) | 95.05 (93.27 to 96.84) |
| Month 6 (n =2048, 557) | 85.64 (84.13 to 87.16) | 93.90 (91.91 to 95.88) |
| Month 12 (n =1775, 525) | 87.66 (86.13 to 89.19) | 93.14 (90.98 to 95.30) |
| Month 24 (n =1393, 445) | 88.87 (87.22 to 90.52) | 94.61 (92.51 to 96.71) |
| Month 36 (n =1118, 380) | 90.97 (89.29 to 92.65) | 92.63 (90.00 to 95.26) |
| Month 48 (n =422, 124) | 88.86 (85.86 to 91.86) | 97.58 (94.88 to 100.00) |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=90% reduction from baseline in PASI scores were reported.
| percentage of participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1 (n =2194, 555) | 29.99 (28.07 to 31.91) | 56.04 (51.91 to 60.17) |
| Month 3 (n =2200, 566) | 33.73 (31.75 to 35.70) | 65.37 (61.45 to 69.29) |
| Month 6 (n =2048, 557) | 35.21 (33.14 to 37.27) | 65.89 (61.95 to 69.83) |
| Month 12 (n =1775, 525) | 35.94 (33.71 to 38.18) | 61.71 (57.56 to 65.87) |
| Month 24 (n =1393, 445) | 38.33 (35.78 to 40.89) | 62.02 (57.51 to 66.53) |
| Month 36 (n =1118, 380) | 43.02 (40.12 to 45.93) | 60.53 (55.61 to 65.44) |
| Month 48 (n =422, 124) | 34.36 (29.83 to 38.89) | 58.06 (49.38 to 66.75) |
PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=125% increase from baseline in PASI scores were reported.
| percentage of participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1 (n =2194, 555) | 0.96 (0.55 to 1.36) | 1.08 (0.22 to 1.94) |
| Month 3 (n =2200, 566) | 1.18 (0.73 to 1.63) | 0.71 (0.02 to 1.40) |
| Month 6 (n =2048, 557) | 1.27 (0.78 to 1.75) | 0.90 (0.11 to 1.68) |
| Month 12 (n =1775, 525) | 0.90 (0.46 to 1.34) | 1.33 (0.35 to 2.31) |
| Month 24 (n =1393, 445) | 0.93 (0.43 to 1.44) | 0.90 (0.02 to 1.78) |
| Month 36 (n =1118, 380) | 0.54 (0.11 to 0.96) | 1.32 (0.17 to 2.46) |
| Month 48 (n =422, 124) | 0.71 (0.00 to 1.51) | 0.00 (0.00 to 0.00) |
ISI assessed severity of itching due to psoriasis. ISI was a single item, horizontal numeric rating scale. Participants were asked to rate their 'severity of itching' due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms '0=no itching' and '10=worst possible itching' at the ends. Higher scores indicated greater severity of itching.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline (n =2172, 566) | 5.76 ± 2.91 | 5.17 ± 3.00 |
| Month 1 (n =2196, 561) | 1.88 ± 2.26 | 0.92 ± 1.53 |
| Month 3 (n =2197, 572) | 1.83 ± 2.32 | 0.72 ± 1.39 |
| Month 6 (n =2047, 560) | 1.87 ± 2.33 | 0.82 ± 1.51 |
| Month 12 (n =1774, 530) | 1.79 ± 2.21 | 1.08 ± 1.67 |
| Month 24 (n =1394, 449) | 1.83 ± 2.23 | 1.01 ± 1.54 |
| Month 36 (n =1117, 383) | 1.69 ± 2.12 | 1.21 ± 1.72 |
| Month 48 (n =417, 127) | 1.92 ± 2.30 | 1.24 ± 1.74 |
ISI assessed severity of itching due to psoriasis. ISI was a single item, horizontal numeric rating scale. Participants were asked to rate their 'severity of itching' due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms '0=no itching' and '10=worst possible itching' at the ends. Higher scores indicated greater severity of itching.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1 (n =2107, 544) | -3.88 ± 3.06 | -4.26 ± 3.07 |
| Month 3 (n =2103, 554) | -3.94 ± 3.18 | -4.44 ± 3.06 |
| Month 6 (n =1958, 543) | -3.91 ± 3.20 | -4.36 ± 3.14 |
| Month 12 (n =1693, 514) | -3.90 ± 3.17 | -4.01 ± 3.30 |
| Month 24 (n =1340, 435) | -3.80 ± 3.14 | -4.11 ± 3.17 |
| Month 36 (n =1078, 372) | -3.95 ± 3.18 | -3.84 ± 3.06 |
| Month 48 (n =411, 126) | -4.03 ± 3.19 | -3.78 ± 3.25 |
The DLQI was a validated, self-administered, 10-item quality-of-life questionnaire that consisted of 10 items that assessed the impact of skin disease on quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each question was scored on a scale of 0=not at all/not relevant to 3=very much. Response from all of the 10 questions were added to derive the DLQI total scores. Total DLQI scores ranges from 0=not at all to 30=very much, with higher scores indicating greater impairment in quality of life.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline (n =2243, 582) | 12.73 ± 7.12 | 10.95 ± 6.61 |
| Month 1 (n =2189, 559) | 4.11 ± 5.23 | 2.14 ± 3.43 |
| Month 6 (n =2028, 557) | 3.68 ± 5.00 | 1.67 ± 3.33 |
| Month 12 (n =1751, 528) | 3.44 ± 4.65 | 1.71 ± 2.92 |
| Month 24 (n =1361, 441) | 3.49 ± 4.71 | 1.94 ± 3.29 |
| Month 36 (n =1093, 372) | 2.97 ± 4.05 | 1.98 ± 3.35 |
| Month 48 (n =407, 124) | 3.20 ± 4.39 | 1.81 ± 2.98 |
The DLQI was a validated, self-administered, 10-item quality-of-life questionnaire that consisted of 10 items that assessed the impact of skin disease on quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each question was scored on a scale of 0=not at all/not relevant to 3=very much. Response from all of the 10 questions were added to derive the DLQI total scores. Total DLQI scores ranges from 0=not at all to 30=very much, with higher scores indicating greater impairment in quality of life.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Month 1 (n =2163, 556) | -8.61 ± 7.00 | -8.75 ± 6.56 |
| Month 6 (n =2005, 554) | -9.14 ± 7.06 | -9.22 ± 6.92 |
| Month 12 (n =1730, 525) | -9.23 ± 6.91 | -9.02 ± 6.68 |
| Month 24 (n =1345, 438) | -9.08 ± 6.82 | -8.47 ± 6.43 |
| Month 36 (n =1083, 369) | -9.47 ± 6.80 | -8.46 ± 6.14 |
| Month 48 (n =404, 122) | -8.99 ± 6.74 | -7.78 ± 6.10 |
The SF-36 questionnaire, version 2, acute was a 36-item generic health status measure. SF-36 evaluated 8 health-related aspects of an individual: physical functioning, role-physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition. Two summary scale scores were computed from the 8 health aspect scores: physical component summary score and mental component summary score. Score range for both summary scales ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline (n =2233, 580) | 47.31 ± 9.38 | 48.94 ± 9.12 |
| Month 6 (n =2025, 557) | 51.78 ± 8.24 | 53.51 ± 7.30 |
| Month 12 (n =1750, 524) | 51.96 ± 8.13 | 53.58 ± 7.19 |
| Month 24 (n =1362, 442) | 51.91 ± 7.80 | 53.15 ± 7.32 |
| Month 36 (n =857, 286) | 52.01 ± 8.08 | 53.05 ± 7.28 |
| Month 48 (n =124, 56) | 52.93 ± 6.79 | 52.36 ± 8.39 |
The SF-36 questionnaire, version 2 was a 36-item generic health status measure. SF-36 evaluated 8 health-related aspects of an individual: physical functioning, role-physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition. Two summary scale scores were computed from the 8 health aspect scores: the Physical Component Summary and the Mental Component Summary. Score range for both summary scale ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline (n =2233, 580) | 43.51 ± 11.98 | 43.96 ± 11.23 |
| Month 6 (n =2025, 557) | 48.86 ± 10.02 | 50.03 ± 9.14 |
| Month 12 (n =1750, 524) | 49.10 ± 9.89 | 49.78 ± 9.28 |
| Month 24 (n =1362, 442) | 49.22 ± 9.82 | 49.66 ± 9.54 |
| Month 36 (n =857, 286) | 49.21 ± 9.95 | 50.17 ± 8.20 |
| Month 48 (n =124, 56) | 50.14 ± 8.96 | 49.60 ± 8.24 |
The PtGA evaluated the overall skin disease of participants at that point in time on a single-item. Participants provided their response on a 5-point scale ranges from: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe. Higher score indicated greater severity of disease. Participants who provided their response as "clear (score of 0)" or "almost clear (score of 1)" in PtGA at each specified visit were reported in this outcome measure.
| participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline: Clear (n =2244, 583) | 1 | 3 |
| Baseline: Almost Clear (n =2244, 583) | 25 | 16 |
| Month 1: Clear (n =2192, 561) | 211 | 127 |
| Month 1: Almost Clear (n =2192, 561) | 703 | 246 |
| Month 3: Clear (n =2177, 568) | 248 | 174 |
| Month 3: Almost Clear (n =2177, 568) | 762 | 254 |
| Month 6: Clear (n =2030, 562) | 247 | 176 |
| Month 6: Almost Clear (n =2030, 562) | 748 | 265 |
| Month 12: Clear (n =1758, 530) | 209 | 151 |
| Month 12: Almost Clear (n =1758, 530) | 662 | 236 |
| Month 24: Clear (n =1380, 449) | 171 | 111 |
| Month 24: Almost Clear (n =1380, 449) | 502 | 202 |
| Month 36: Clear (n =1112, 377) | 162 | 75 |
| Month 36: Almost Clear (n =1112, 377) | 418 | 183 |
| Month 48: Clear (n =410, 125) | 40 | 25 |
| Month 48: Almost Clear (n =410, 125) | 151 | 60 |
EQ-5D: participant rated 5-dimension (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) questionnaire to assess health-related quality of life in terms of a single utility score. Each dimension was assessed on a 3-point scale (1=no problems, 2=some problems, 3=extreme problems, where higher scores=worse health condition). The responses from the 5 dimensions were used to calculate a single utility index value. Scoring formula developed by EuroQol Group assigned a utility value for each dimension in the profile. Score was transformed and results in a total score range -0.594 to 1.000; higher score indicated a better health state.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline (n =2242, 581) | 0.77 ± 0.19 | 0.80 ± 0.17 |
| Month 6 (n =2021, 559) | 0.87 ± 0.15 | 0.91 ± 0.13 |
| Month 12 (n =1750, 523) | 0.88 ± 0.15 | 0.91 ± 0.13 |
| Month 24 (n =1364, 443) | 0.88 ± 0.14 | 0.90 ± 0.14 |
| Month 36 (n =857, 284) | 0.88 ± 0.14 | 0.91 ± 0.12 |
| Month 48 (n =124, 56) | 0.90 ± 0.13 | 0.89 ± 0.12 |
EQ-5D VAS was a participant rated questionnaire to assess health-related quality of life in terms of a single index value. It was a visual analogue scale that ranged from 0 (minimum) to 100 (maximum), with higher scores indicating a better health condition.
| units on a scale | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline (n =2224, 570) | 66.39 ± 23.20 | 68.21 ± 22.91 |
| Month 6 (n =2026, 559) | 78.28 ± 17.11 | 83.95 ± 16.18 |
| Month 12 (n =1749, 525) | 78.91 ± 16.95 | 83.80 ± 14.85 |
| Month 24 (n =1365, 443) | 79.80 ± 16.98 | 83.47 ± 15.55 |
| Month 36 (n =856, 286) | 79.43 ± 17.01 | 84.62 ± 14.28 |
| Month 48 (n =124, 56) | 82.14 ± 14.07 | 84.50 ± 16.87 |
Ps-HCRU was a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. In the first section, it assessed direct costs associated with healthcare resource use which included participant's interactions with healthcare providers such as general practitioners, dermatologists, cardiologists, gastroenterologists, psychiatrists, surgeons and nurses. When taking the evening dose of tofacitinib, participants were asked to answer the Ps-HCRU questionnaire only if they had an interaction with a healthcare provider or their work was impacted by psoriasis on that specified day. In this outcome measure, number of participants who answered Ps-HCRU at any specified visits were reported.
| participants | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| Baseline | 156 | 44 |
| Month 1 | 153 | 30 |
| Month 3 | 204 | 55 |
| Month 6 | 288 | 71 |
| Month 12 | 234 | 71 |
| Month 24 | 171 | 50 |
| Month 36 | 114 | 30 |
| Month 48 | 22 | 11 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 10 mg | — | 304/2,281 (13.3%) | 1,415/2,281 (62%) |
| Tofacitinib 5 mg or 10 mg | — | 88/586 (15%) | 394/586 (67.2%) |
| Event | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| PneumoniaInfections and infestations | 16/2281 | 5/586 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/2281 | 4/586 |
| Ankle fractureInjury, poisoning and procedural complications | 1/2281 | 3/586 |
| FallInjury, poisoning and procedural complications | 0/2281 | 3/586 |
| Breast painReproductive system and breast disorders | 0/640 | 1/203 |
| MetrorrhagiaReproductive system and breast disorders | 0/640 | 1/203 |
| Pelvic haematomaReproductive system and breast disorders | 0/640 | 1/203 |
| Angina pectorisCardiac disorders | 2/2281 | 2/586 |
| Myocardial infarctionCardiac disorders | 6/2281 | 2/586 |
| VertigoEar and labyrinth disorders | 1/2281 | 2/586 |
| Event | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 476/2281 | 122/586 |
| Blood creatine phosphokinase increasedInvestigations | 294/2281 | 92/586 |
| Upper respiratory tract infectionInfections and infestations | 264/2281 | 51/586 |
| DyslipidaemiaMetabolism and nutrition disorders | 73/2281 | 52/586 |
| BronchitisInfections and infestations | 134/2281 | 48/586 |
| HypertensionVascular disorders | 169/2281 | 44/586 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 164/2281 | 40/586 |
| Urinary tract infectionInfections and infestations | 145/2281 | 42/586 |
| PsoriasisSkin and subcutaneous tissue disorders | 148/2281 | 39/586 |
| Gamma-glutamyltransferase increasedInvestigations | 81/2281 | 38/586 |
Safety analysis set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg | Total |
|---|---|---|---|
| Mean | 45.3 ± 12.5 | 47.0 ± 13.0 | 45.6 ± 12.6 |
| Sex: Female, Male(Participants) | Tofacitinib 10 mg | Tofacitinib 5 mg or 10 mg | Total |
|---|---|---|---|
| Female | 640 | 203 | 843 |
| Male | 1641 | 383 | 2024 |
Showing the first 100 of 323 sites across 36 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
The record gives a start of Sep 2010, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib